A radiopharmaceutical can be conjugated with radioactive isotopes for use either in diagnosis (e.g. low doses of radiations that do not harm patients) or treatment, with radioactive isotopes that emit damaging radiation to kill tumour cells. Continued identification of new tumour‐specific targets and the development of targeting agent are key to the development of new therapeutics, which are urgently needed to improve the outcome of treatment resistant cancer. Our lab is evaluating therapeutic version of our imaging compounds which are radiolabeled either with beta-emitters such as 177Lu or alpha emitters, 225Ac.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.